CYTK vs. SMH

In the year-to-date period, CYTK achieves a -31.70% return, which is significantly lower than SMH's -1.97% return. Over the past 10 years, CYTK has underperformed SMH with an annualized return of 18.42%, while SMH has yielded a comparatively higher 25.08% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Cytokinetics, Incorporated (CYTK) and VanEck Vectors Semiconductor ETF (SMH). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current CYTK Sharpe Ratio is -0.94, which is lower than the SMH Sharpe Ratio of 0.16. The chart below compares the historical Sharpe Ratios of CYTK and SMH, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

CYTK has not paid dividends to shareholders, while SMH's dividend yield for the trailing twelve months is around 0.45%.

The maximum CYTK drawdown since its inception was -97.09%, which is greater than SMH's maximum drawdown of -83.29%. Use the drawdown chart below to compare losses from any high point for CYTK and SMH. For additional features, visit the drawdowns tool.

Cytokinetics, Incorporated (CYTK) has a higher volatility of 19.34% compared to VanEck Vectors Semiconductor ETF (SMH) at 10.91%. This indicates that CYTK's price experiences larger fluctuations and is considered to be riskier than SMH based on this measure. The chart below showcases a comparison of their rolling one-month volatility.